drugset / Trial / NCT04197323

Alprostadil Liposomes for Injection for Lower Extremity Arteriosclerosis Obliteran

NCT04197323

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a randomized, positive-control, multicenter, multiple-dose, dose-escalation phase II trial

Timeline

Start
2019-10-01
Primary completion
2021-06-01
Completion
2021-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Alprostadil Unknown 40 ug
Subject Alprostadil Unknown 80 ug
Subject Alprostadil Unknown 120 ug